Goat Anti-EBF1 _ COE1, with HRP-conjugated secondary antibody
- Known as:
- Goat Antibody toEBF1 _ COE1, horseradish peroxidase-labelled secondary detector ab (anti-)
- Catalog number:
- 126-10124
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Ray Biotech
- Gene target:
- Goat Anti-EBF1 _ COE1 with HRP-conjugated secondary antibody
Related genes to: Goat Anti-EBF1 _ COE1, with HRP-conjugated secondary antibody
- Gene:
- EBF1 NIH gene
- Name:
- EBF transcription factor 1
- Previous symbol:
- EBF
- Synonyms:
- OLF1, COE1
- Chromosome:
- 5q33.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-23
- Date modifiied:
- 2018-09-21
Related products to: Goat Anti-EBF1 _ COE1, with HRP-conjugated secondary antibody
Related articles to: Goat Anti-EBF1 _ COE1, with HRP-conjugated secondary antibody
- - Source: PubMed
Publication date: 2025/03/21
Fedl Anna STagoh HiromiGruenbacher SarahSun QiongSchenk Robyn LFroussios KimonJaritz MarkusBusslinger MeinradSchwickert Tanja A - DNA methylation influences gene expression and is involved in numerous biological processes, including fat production. It is involved in lipid generation in numerous animal species, including poultry. However, the effect of DNA methylation on adipogenesis in chickens remains unclear. - Source: PubMed
Publication date: 2025/03/20
Chao XiaohuanGuo LijinHu MeilingYe MaoFan ZhexiaLuan KangChen JiahaoZhang ChunleiLiu ManqingZhou BoZhang XiquanLi ZhenhuiLuo Qingbin - The skin, the largest organ in the human body, is composed of complex layers that include subcutaneous adipose tissue. Understanding the characteristics of this skin structure is essential to optimize therapeutic interventions, such as cryolipolysis, aiming for more effective and personalized results. - Source: PubMed
Palauro C RtPalmeira Silva Daumas P SCarreiro E MPimentel de Almeida FDias I LMeyer P F - Although the identification of disease subtypes conveying prognostic significance along with minimal residual disease (MRD) assessment represent cornerstones for stratification in childhood acute lymphoblastic leukemia (ALL), approximately half of the relapses occur in patients from standard-risk groups. Identification of the drivers of treatment failure is crucial for detection of high-risk clones at diagnosis. We evaluated clinical variables and the most common genetic alterations in an unselected cohort of 55 patients with B-ALL treated according to the ALL-IC-BFM 2002 protocol, with a median follow-up of 46 months. Matched diagnosis-relapse samples underwent screening for additional alterations using whole-exome sequencing. Mutations in the gene were found in 80% (4/5) of the patients with relapse, either present from the disease onset or acquired at relapse, while none of the examined patients in remission presented alterations in this gene. Deletions in and (present in 2/5 and 1/5 of the patients with relapse, respectively) were infrequent or absent in the patients in remission, respectively. Screening for alterations in the gene at diagnosis and/or at multiple time-points during chemotherapy could be incorporated into treatment protocols, as it may contribute to the identification of significant number of patients with predefined or acquired chemoresistant clones. - Source: PubMed
Publication date: 2025/03/06
Krstevska Bozhinovikj EMatevska-Geshkovska NStaninova Stojovska MGjorgievska EJovanovska AKocheva SDimovski A - Studies show that caveolin genes are associated with metabolic disorders, so we aimed to systematically review the association between caveolin genes and metabolic syndrome in human studies. This systematic review is conducted based on the PRISMA 2020 checklist. - Source: PubMed
Publication date: 2025/01/31
Arefian MohadesehMazaheri-Tehrani SadeghYazdi MaryamKelishadi Roya